{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:06:00Z","timestamp":1781715960532,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007658","name":"Crohn\u2019s and Colitis Canada","doi-asserted-by":"publisher","award":["626347"],"award-info":[{"award-number":["626347"]}],"id":[{"id":"10.13039\/501100007658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022437","name":"CH.I.L.D. Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022437","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012285","name":"BC Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bmcl.2025.130093","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:03:19Z","timestamp":1736380999000},"page":"130093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of novel GI-centric prostaglandin E2 receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases"],"prefix":"10.1016","volume":"119","author":[{"given":"Srinivas","family":"Kantham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe R.","family":"Cantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-2752","authenticated-orcid":false,"given":"Jocelyn J.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3213-7568","authenticated-orcid":false,"given":"Hyungjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-6542","authenticated-orcid":false,"given":"Kevin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiana","family":"Lassueur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1345-6747","authenticated-orcid":false,"given":"Bruce A.","family":"Vallance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-8557","authenticated-orcid":false,"given":"Kevan","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130093_b0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/cs0780119","article-title":"Mechanism of action of 5-aminosalicylic acid and its derivatives","volume":"78","author":"Ireland","year":"1990","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.bmcl.2025.130093_b0010","first-page":"1098","article-title":"Drugs used in the treatment of gastrointestinal diseases","volume":"12","author":"McQuaid","year":"2007","journal-title":"Basic Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130093_b0015","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1023\/A:1005517112039","article-title":"5-Aminosalicylic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer","volume":"45","author":"Brown","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bmcl.2025.130093_b0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-2000-135","article-title":"Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel","volume":"32","author":"Reinacher-Schick","year":"2000","journal-title":"Endoscopy"},{"key":"10.1016\/j.bmcl.2025.130093_b0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1572-0241.2006.00330.x","article-title":"Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study","volume":"101","author":"Bernstein","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bmcl.2025.130093_b0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.1365-3083.2002.01096.x","article-title":"Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329","volume":"56","author":"Nitta","year":"2002","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.bmcl.2025.130093_b0035","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.bmcl.2025.130093_b0040","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0016-5085(19)31672-5","article-title":"Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine","volume":"75","author":"Sharon","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmcl.2025.130093_b0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0090-6980(99)00032-5","article-title":"Effects of ulcerative colitis activity on plasma and mucosal prostaglandin E2 concentration","volume":"58","author":"Wierci\u0144ska-Drapa\u0142o","year":"1999","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bmcl.2025.130093_b0050","doi-asserted-by":"crossref","first-page":"G1097","DOI":"10.1152\/ajpgi.00280.2010","article-title":"Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity","volume":"299","author":"Lejeune","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.bmcl.2025.130093_b0055","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI0214459","article-title":"The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut","volume":"109","author":"Kabashima","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bmcl.2025.130093_b0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1006\/bbrc.2000.3779","article-title":"Prostaglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils","volume":"278","author":"Yamane","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmcl.2025.130093_b0065","doi-asserted-by":"crossref","first-page":"44147","DOI":"10.1074\/jbc.M204810200","article-title":"Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor","volume":"277","author":"Takayama","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130093_b0070","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1183\/09031936.00131606","article-title":"Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages","volume":"29","author":"Ratcliffe","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2025.130093_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110264","article-title":"Prostaglandin E receptor EP4 stimulates lymphangiogenesis to promote mucosal healing during DSS-induced colitis","volume":"128","author":"Hosono","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130093_b0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1124\/jpet.106.111146","article-title":"The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration","volume":"320","author":"Jiang","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2025.130093_b0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ibd.21080","article-title":"Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial","volume":"16","author":"Nakase","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bmcl.2025.130093_b0090","unstructured":"U. M. I. N.-C. T. R. C. Clinical Trial. A phase 1 clinical pharmacological study with repeated oral doses of KAG-308; 2014. https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000016317."},{"key":"10.1016\/j.bmcl.2025.130093_b0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.shk.0000129338.99410.5d","article-title":"A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production","volume":"22","author":"Sakamoto","year":"2004","journal-title":"Shock"},{"key":"10.1016\/j.bmcl.2025.130093_b0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1054\/plef.2000.0144","article-title":"Prostanoid receptors in intestinal epithelium: selective expression, function, and change with inflammation","volume":"63","author":"Takafuji","year":"2000","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.bmcl.2025.130093_b0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3987\/COM-04-S(P)47","article-title":"Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist","volume":"64","author":"Young","year":"2004","journal-title":"Heterocycles"},{"key":"10.1016\/j.bmcl.2025.130093_b0110","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0960-894X(03)00042-8","article-title":"Discovery of a potent and selective agonist of the prostaglandin EP4 receptor","volume":"13","author":"Billot","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130093_b0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcmgh.2015.01.006","article-title":"Experimental models of inflammatory bowel diseases","volume":"1","author":"Kiesler","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.bmcl.2025.130093_b0120","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41556-021-00708-8","article-title":"E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis","volume":"23","author":"Patankar","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130093_b0125","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/1568026611313070002","article-title":"Intestinal targeting of drugs: rational design approaches and challenges","volume":"13","author":"Filipski","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2025.130093_b0130","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1021\/acsptsci.1c00027","article-title":"Design, synthesis, pharmacokinetics, and biodistribution of a series of bone-targeting EP4 receptor agonist prodrugs for treatment of osteoporosis and other bone conditions","volume":"4","author":"Th\u00e9venin","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmcl.2025.130093_b0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130093_b0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.110.032151","article-title":"Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation","volume":"38","author":"Sweeny","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmcl.2025.130093_b0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/128_2014_561","article-title":"Prodrugs of phosphonates and phosphates: crossing the membrane barrier","volume":"360","author":"Wiemer","year":"2015","journal-title":"TOP Curr Chem"},{"key":"10.1016\/j.bmcl.2025.130093_b0150","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1073\/pnas.0712140105","article-title":"Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition","volume":"105","author":"Goldberg","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2025.130093_b0155","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0026-895X(25)09407-6","article-title":"Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist","volume":"50","author":"Nishigaki","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130093_b0160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.bmcl.2025.130093_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2191-219X-3-60","article-title":"Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT","volume":"3","author":"Padmanabhan","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.bmcl.2025.130093_b0170","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fphar.2020.00524","article-title":"Advances in oral drug delivery for regional targeting in the gastrointestinal tract-influence of physiological, pathophysiological and pharmaceutical factors","volume":"11","author":"Hua","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130093_b0175","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/jm900080g","article-title":"Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir","volume":"52","author":"DeGoey","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130093_b0180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12950-020-00256-2","article-title":"Tissue alkaline phosphatase activity and expression in an experimental infant swine model of cardiopulmonary bypass with deep hypothermic circulatory arrest","volume":"17","author":"Khailova","year":"2020","journal-title":"J Inflamm (Lond)"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T03:38:26Z","timestamp":1740454706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":36,"alternative-id":["S0960894X25000022"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130093","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel GI-centric prostaglandin E2 receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130093"}}